201 related articles for article (PubMed ID: 37787851)
1.
Liu C; Ma G; Zhang J; Cheng J; Yang Z; Song S
Ann Nucl Med; 2023 Dec; 37(12):675-684. PubMed ID: 37787851
[TBL] [Abstract][Full Text] [Related]
2. Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition.
Boers J; Venema CM; de Vries EFJ; Glaudemans AWJM; Kwee TC; Schuuring E; Martens JWM; Elias SG; Hospers GAP; Schröder CP
Eur J Cancer; 2020 Feb; 126():11-20. PubMed ID: 31891878
[TBL] [Abstract][Full Text] [Related]
3. The Predictive Value of Early Changes in
He M; Liu C; Shi Q; Sun Y; Zhang Y; Xu X; Yuan H; Zhang Y; Liu Y; Liu G; Di G; Yang Z; Wang Z; Shao Z
Oncologist; 2020 Nov; 25(11):927-936. PubMed ID: 32272493
[TBL] [Abstract][Full Text] [Related]
4. Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer.
Kurland BF; Peterson LM; Lee JH; Schubert EK; Currin ER; Link JM; Krohn KA; Mankoff DA; Linden HM
Clin Cancer Res; 2017 Jan; 23(2):407-415. PubMed ID: 27342400
[TBL] [Abstract][Full Text] [Related]
5. Dual Tracers of 16α-[18F]fluoro-17β-Estradiol and [18F]fluorodeoxyglucose for Prediction of Progression-Free Survival After Fulvestrant Therapy in Patients With HR+/HER2- Metastatic Breast Cancer.
Liu C; Xu X; Yuan H; Zhang Y; Zhang Y; Song S; Yang Z
Front Oncol; 2020; 10():580277. PubMed ID: 33251143
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of tumour heterogeneity by
Liu C; Hu S; Xu X; Zhang Y; Wang B; Song S; Yang Z
Breast Cancer Res; 2022 Aug; 24(1):57. PubMed ID: 36028895
[TBL] [Abstract][Full Text] [Related]
7.
Liu C; Gong C; Liu S; Zhang Y; Zhang Y; Xu X; Yuan H; Wang B; Yang Z
Oncologist; 2019 Dec; 24(12):e1277-e1285. PubMed ID: 31337657
[TBL] [Abstract][Full Text] [Related]
8. Head-to-Head Evaluation of
Ulaner GA; Jhaveri K; Chandarlapaty S; Hatzoglou V; Riedl CC; Lewis JS; Mauguen A
J Nucl Med; 2021 Mar; 62(3):326-331. PubMed ID: 32680923
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT.
Bottoni G; Piccardo A; Fiz F; Siri G; Matteucci F; Rocca A; Nanni O; Monti M; Brain E; Alberini JL; Dib B; Sacchetti GM; Saggia C; Rossi V; Harbeck N; Wuerstlein R; Degenhardt T; DeCensi A; Rollandi GA; Gennari A
Eur J Radiol; 2021 Aug; 141():109821. PubMed ID: 34139575
[TBL] [Abstract][Full Text] [Related]
10. [18F]-Fluorodeoxyglucose Positron Emission Tomography/CT to Assess the Early Metabolic Response in Patients with Hormone Receptor-Positive HER2-Negative Metastasized Breast Cancer Treated with Cyclin-Dependent 4/6 Kinase Inhibitors.
Seifert R; Küper A; Tewes M; Heuschmid M; Welt A; Fendler WP; Herrmann K; Decker T
Oncol Res Treat; 2021; 44(7-8):400-407. PubMed ID: 34102639
[TBL] [Abstract][Full Text] [Related]
11. [18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant.
Iqbal R; Yaqub M; Bektas HO; Oprea-Lager DE; de Vries EGE; Glaudemans AWJM; Aftimos P; Gebhart G; Beelen AP; Schuit RC; Windhorst AD; Boellaard R; Menke-van der Houven van Oordt CW
Clin Cancer Res; 2023 Jun; 29(11):2075-2084. PubMed ID: 36735488
[TBL] [Abstract][Full Text] [Related]
12. Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with
Gennari A; Brain E; De Censi A; Nanni O; Wuerstlein R; Frassoldati A; Cortes J; Rossi V; Palleschi M; Alberini JL; Matteucci F; Piccardo A; Sacchetti G; Ilhan H; D'Avanzo F; Ruffilli B; Nardin S; Monti M; Puntoni M; Fontana V; Boni L; Harbeck N;
Ann Oncol; 2024 Jun; 35(6):549-558. PubMed ID: 38423389
[TBL] [Abstract][Full Text] [Related]
13. Does Measurement of First-Order and Heterogeneity Parameters Improve Response Assessment of Bone Metastases in Breast Cancer Compared to SUV
Azad GK; Cousin F; Siddique M; Taylor B; Goh V; Cook GJR
Mol Imaging Biol; 2019 Aug; 21(4):781-789. PubMed ID: 30250989
[TBL] [Abstract][Full Text] [Related]
14. Total Lesion Glycolysis Levels as Predictive Indicators in Patients With Metastatic and Recurrent Breast Cancer Undergoing Endocrine Therapy With or Without CDK4/6 Inhibitor.
Ozawa H; Higuchi T; Fujimoto Y; Bun A; Fukui R; Kanaoka H; Nagahashi M; Kitajima K; Yamakado K; Miyoshi Y
Anticancer Res; 2022 Oct; 42(10):4813-4824. PubMed ID: 36191999
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment
Gong C; Ma G; Hu X; Zhang Y; Wang Z; Zhang J; Zhao Y; Li Y; Xie Y; Yang Z; Wang B
Oncologist; 2018 Oct; 23(10):1144-1152. PubMed ID: 30082489
[TBL] [Abstract][Full Text] [Related]
16. Can
Gupta M; Datta A; Choudhury PS; Dsouza M; Batra U; Mishra A
World J Nucl Med; 2017; 16(2):133-139. PubMed ID: 28553180
[TBL] [Abstract][Full Text] [Related]
17. Case report:
Pan B; Hao Z; Xu Y; Wang Z; Yao R; Wang X; Ren C; Zhou Y; Sun Q; Huo L
Front Oncol; 2022; 12():1095779. PubMed ID: 36620595
[TBL] [Abstract][Full Text] [Related]
18. The Assessment of Estrogen Receptor Status and Its Intratumoral Heterogeneity in Patients With Breast Cancer by Using 18F-Fluoroestradiol PET/CT.
Yang Z; Sun Y; Xu X; Zhang Y; Zhang J; Xue J; Wang M; Yuan H; Hu S; Shi W; Zhu B; Zhang Y
Clin Nucl Med; 2017 Jun; 42(6):421-427. PubMed ID: 28221191
[TBL] [Abstract][Full Text] [Related]
19. Can fluorine-18 fluoroestradiol positron emission tomography-computed tomography demonstrate the heterogeneity of breast cancer in vivo?
Yang Z; Sun Y; Zhang Y; Xue J; Wang M; Shi W; Zhu B; Hu S; Yao Z; Pan H; Zhang Y
Clin Breast Cancer; 2013 Oct; 13(5):359-63. PubMed ID: 23787040
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of
Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
